Meibomian gland dysfunction (MGD) is the major cause of evaporative dry eye disease (EDED) and dysfunction is widely thought to mechanistically involve ductal hyperkeratinization, plugging and ...

The National Eye Institute, part of the National Institutes of Health, awarded Jason J. Nichols, OD, MPH, PhD, FAAO, a five-year, $1.9 million R01 grant to study potential molecular markers in ...

Dry eye disease is a condition that afflicts millions of people worldwide, causing constant discomfort and affecting their quality of life. One of the key culprits behind this condition is meibomian ...

Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — Efforts are under way to establish design standards for clinical trials on diagnosis and ...

Please provide your email address to receive an email when new articles are posted on . Two new treatment options are helping clinicians experience better outcomes when dealing with meibomian gland ...

"DelveInsight’s, “Meibomian Gland Dysfunction- Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Meibomian Gland Dysfunction pipeline landscape ...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Meibomian Gland Dysfunction pipeline constitutes 4+ key companies continuously working towards developing 4+ Meibomian ...

SAN DIEGO — Omega-3 fatty acid supplementation improves the signs and symptoms of meibomian gland dysfunction, a new study shows. This study supports the potential of omega-3 fatty acids to prevent ...

Twenty eyes of 20 vitiligo patients (Group 1) and 20 eyes of 20 healthy individuals (Group 2) were enrolled. All subjects had undergone a comprehensive ophthalmic examination including corneal and ...

Meibomian gland dysfunction occurs when the eye glands are not able to secrete sufficient oil or when the oil secreted is of poor quality. It may cause irritation, eye inflammation and increase dry ...

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing AZR-MD-001, an investigational, potentially first-in-class, Ophthalmic Keratolytic targeting Meibomian Gland Dysfunction ...